Archive for the ‘Pharma / Biotech Industry’ Category

Blood Testing to Treat Mood Disorders

Monday, March 3rd, 2008

(Ivanhoe Newswire) — Blood testing for mood disorders may help the medical community come up with better treatments for the conditions.

Currently, there are no blood tests for mood disorders. And relying on patients to rate the severity of their symptoms and on the clinicians’ impression may limit the chances of effective treatment and new drug development.

Researchers from Indiana University School of Medicine instead propose a new way to help identify blood biomarkers to help determine mood state.

(more…)

New Treatment for Heart Arrhythmias

Monday, March 3rd, 2008

PHILADELPHIA, Pa. (Ivanhoe Newswire) — One moment you feel fine. The next, your heart is racing at almost double the pace. Atrial fibrillation affects more than two million Americans. Although it is the most common arrhythmia, medicines for the condition only work about half the time. Now, researchers are testing a new tool that may help put a patient’s heart back on track.

 

Fifty-six year old Tom Calvaresi is the driving force behind his family winery. So when his heart started feeling funny, he didn’t ignore it.

(more…)

Hand Arthritis

Friday, February 15th, 2008

If you’re new here, you may want to subscribe to my RSS feed.Thanks for visiting!

juvenile rhuematoid arthritis knee disorders living with arthritis lupus polymyalgia rheumatica rheumatoid arthritis sjorgen syndrome: Blood disorders

Arthritis
Ciyy biofedback medicine fir arthritis i kyme disease arthritis intormation on osteoarthritis arthitis creams rhuematoid arthritis sympton, wist heumatoid arthritis flare

Arthritis: Rheumatoid Arthritis And Fatige, Arthritis Gloves
(more…)

Post Traumatic Stress Is a Risk Factor for Chronic Disease

Friday, February 15th, 2008

(Ivanhoe Newswire)  Veterans with Post Traumatic Stress Disorder (PTSD) are just as likely to have long term health problems as people with chronic disease risk factors like high white blood cell counts.  However, very few healthcare providers screen PTSD patients for these biological markers.

“Exposure to trauma has not only psychological effects, but it can take a serious toll on a person’s health status and biological function as well,” said Geisinger Health Systems Senior Investigator Joseph Boscarino, PhD, MPH.  “PTSD is a risk factor for disease that doctors should put on their radar screens.”

(more…)

Alternative Medicine And Mental Health Care

Wednesday, February 6th, 2008

If you’re new here, you may want to subscribe to my RSS feed.Thanks for visiting!

Classical Homeopathy - natural, holistic, alternative medicine Mental Health - Depression, Anxiety, PTSD, mental illness Learning and behavioral disorders, foster care

Mental Health HEALTH RESOURCES UK MASSAGE LONDON ALTERNATIVE MEDICINE
Aetna Health Care Affordable Health Care Alternative Health Alternative Medicine Animal Health Aromatherapy Canada Health Cancer Health Cat Health Centrum Multivitamin

(more…)

Abuse Worsens IBS Pain

Wednesday, February 6th, 2008

(Ivanhoe Newswire) — Women with a history of physical and/or sexual abuse may be more susceptible to the pain and suffering associated with irritable bowel syndrome (IBS).

According to researchers from UCLA and the University of North Carolina who conducted brain imaging studies on women with IBS, those with abuse in their backgrounds were less likely to be able to “turn off” a specific pain mechanism in the brain as women who also had IBS but didn’t have a history of abuse.

(more…)

Boehringer Ingelheim and Eli Lilly change Yentreve AriClaim deal

Friday, December 21st, 2007


Eli Lilly is to buy back worldwide marketing rights for Yentreve/AriClaim (duloxetine hydrochloride) from Boehringer Ingelheim. As a stress urinary incontinence (SUI) treatment, along with future related urinary incontinence indications, the drug will continue to be marketed outside the US by Lilly but other treatments using duloxetine will remain under both firms.

Lilly president and chief operating officer John Lechleiter said: “Based on our collective experiences to date in the marketplace, both companies believe that the Yentreve/AriClaim opportunity is best suited and can be best commercialised in markets outside the US with the support of one company. “This is about ‘right sizing’ our investments to address our greatest opportunities and the greatest patient needs.” Dr Alessandro Banchi, Boehringer Ingelheim chairman of the board of managing directors, added: “There has been an excellent spirit of collaboration in our alliance with Lilly.
(more…)

CALPIRG Members Speak Out on Health Care

Friday, December 21st, 2007

Health care reform is at the top of California’s agenda, and everyone agrees the system is broken. It’s harder to know which problems are the most important, and easy to lose sight of what’s really at stake in the abstract policy debates.That’s why CALPIRG recently conducted an email survey of 575 of our members, to find out what kind of reforms are most important to them, and gather their stories about the health care system.
(more…)

New Statin Free Drug is Effective at Cutting Heart Attack Risk

Thursday, December 20th, 2007

(Ivanhoe Newswire) – A new and different kind of cholesterol-lowering drug is proving safe and effective at reducing the risk of heart disease.

In its first clinical trial, the new drug, known only as KB2115, has been shown to cut low density lipoprotein ‘bad’ cholesterol (LDL) by 40%. The best drug trial using cholesterol cutting statins show that they reduce the incidence of new heart attacks by only 35%.

KB2115 mimics the action of thyroid hormone and safely speeds up the hormone’s natural ability to get rid of LDL out of the body. Until now, efforts to attack cholesterol using drugs that mimic thyroid hormone have been unsuccessful because in addition to the (more…)

New Docs Need Drug Company Training

Thursday, December 20th, 2007

(Ivanhoe Newswire) – If you watch TV, you probably thinking pharmaceutical companies are spending their last dollar to get you to try their drugs.

In reality, however, the bulk of the pharmaceutical industry’s advertising budget goes to convince doctors of the merits of their medications. A new study conducted by investigators from the Indiana School of Medicine and the Regenstrief Institute, Inc., looked at how pharmaceutical company contact early in a doctor’s training might impact his or her attitudes about these companies.

The researchers reviewed 12 studies conducted over the past 16 years, finding medical schools made the most impact on doctor-company relationships when they simply refused to allow companies any contact with students. These students ended up being more skeptical about information received from drug companies when they became full-fledged doctors.

(more…)